Association of Helicobacter pylori infection with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors

Table 3 Multivariate analysis for overall survival and progression-free survival in the pooled cohort

	Overall Survival		Progression-free Survival
Variable	HR (95%CI)	P value	HR (95%CI)	P value
Gender				0.096
Male	1[Reference]	0.999	1[Reference]
Female	1.00(0.56–2.02)		0.60(0.33–1.10)
Age (years)		0.858		0.395
< 65	1[Reference]		1[Reference]
≥ 65	1.06(0.56–2.02)		0.76(0.40–1.44)
ECOG PS		0.001*		0.003*
0–1	1[Reference]		1[Reference]
≥ 2	3.49(1.64–7.44)		2.82(1.43–5.58)
Primary tumor site		0.885		0.628
Gastro-esophageal unction	1[Reference]		1[Reference]
Stomach	0.95(0.47–1.94)		0.86(0.46–1.61)
Stage		0.129		0.134
III	1[Reference]		1[Reference]
IV	2.05(0.81–5.16)		1.90(0.82–4.37)
Lines of immunotherapy		0.040*		0.012*
< 2	1[Reference]		1[Reference]
≥ 2	2.00(1.03–3.90)		2.22(1.19–4.12)
Combined with other therapies		0.041*		0.148
No	1[Reference]		1[Reference]
Yes	0.55(0.31–0.98)		0.69(0.41–1.14)
H. pylori status		0.052		0.022*
Negative	1[Reference]		1[Reference]
Positive	1.76(0.99–3.12)		1.90(1.10–3.30)

ECOG PS Eastern Cooperative Oncology Group Performance Status, HR Hazards ratio, CI Confidence interval
^*, P < 0.05 indicates statistical significance

ISSN: 1471-2407